PLoS By Category | Recent PLoS Articles

Oncology - Urology


Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells
Published: Monday, July 18, 2011
Author: Nagireddy Putluri et al.

by Nagireddy Putluri, Ali Shojaie, Vihas T. Vasu, Srilatha Nalluri, Shaiju K. Vareed, Vasanta Putluri, Anuradha Vivekanandan-Giri, Jeman Byun, Subramaniam Pennathur, Theodore R. Sana, Steven M. Fischer, Ganesh S. Palapattu, Chad J. Creighton, George Michailidis, Arun Sreekumar

Prostate cancer is the second leading cause of cancer related death in American men. Development and progression of clinically localized prostate cancer is highly dependent on androgen signaling. Metastatic tumors are initially responsive to anti-androgen therapy, however become resistant to this regimen upon progression. Genomic and proteomic studies have implicated a role for androgen in regulating metabolic processes in prostate cancer. However, there have been no metabolomic profiling studies conducted thus far that have examined androgen-regulated biochemical processes in prostate cancer. Here, we have used unbiased metabolomic profiling coupled with enrichment-based bioprocess mapping to obtain insights into the biochemical alterations mediated by androgen in prostate cancer cell lines. Our findings indicate that androgen exposure results in elevation of amino acid metabolism and alteration of methylation potential in prostate cancer cells. Further, metabolic phenotyping studies confirm higher flux through pathways associated with amino acid metabolism in prostate cancer cells treated with androgen. These findings provide insight into the potential biochemical processes regulated by androgen signaling in prostate cancer. Clinically, if validated, these pathways could be exploited to develop therapeutic strategies that supplement current androgen ablative treatments while the observed androgen-regulated metabolic signatures could be employed as biomarkers that presage the development of castrate-resistant prostate cancer.
  More...

 
//-->